We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced that it has submitted a supplemental new drug application (sNDA) seeking expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States.
Prezcobix is a two-drug fixed-dose combination tablet for treating HIV-1 infection in treatment-naïve and treatment-experienced adults and adolescent patients weighing at least 40 kg. It combines darunavir, J&J’s HIV-1 protease inhibitor, and cobicistat, Gilead Sciences’ (GILD - Free Report) CYP3A inhibitor. J&J markets darunavir as Prezista, as a single agent, in the United States and Gilead markets cobicistat by the name of Tybost.
So far this year, J&J’s shares have declined 5.7% against the industry’s 17.3% increase.
Image Source: Zacks Investment Research
The sNDA seeks approval of Prezcobix for treatment-naïve and treatment-experienced pediatric patients aged 6 and older weighing at least 25 kg who have no viral resistance mutations associated with darunavir. A similar label expansion application has also been submitted to the European Medicines Agency (EMA) for expanded use of Rezolsta for pediatric patients in Europe. Rezolsta is Prezcobix’s brand name in Europe.
Prezcobix/Rezolsta is also marketed under a collaboration between J&J and Gilead. The companies have developed a separate new combination tablet containing a weight-adjusted pediatric dose (darunavir 675 mg/cobicistat 150 mg) for younger kids.
Other than Prezista and Prezcobix/Rezolsta, J&J also markets a darunavir-based once-daily single-tablet regimen (STR) called Symtuza.
Other than J&J and Gilead, another key player in the HIV market is GSK plc (GSK - Free Report) via its HIV subsidiary, ViiV Healthcare. GSK generates the majority of its HIV sales from its dolutegravir franchise, comprising three-drug regimens — Triumeq and Tivicay — and two-drug regimens — Dovato and Juluca. Some of its new long-acting medicines are Cabenuva and Apretude, which are also witnessing strong patient demand and contributing to sales growth. GSK’s HIV sales rose 13% at constant exchange rates in 2023. HIV sales are projected to grow in the high single-digit to low double-digit range in 2024.
In the past 60 days, 2024 estimates for Bioventus have improved from 16 cents per share to 27 cents per share. For 2025, earnings estimates have improved from 40 cents to 43 cents per share in the past 60 days. So far this year, shares of BVS are up 27.1%.
Earnings of Bioventus beat estimates in three of the last four quarters while missing in one, delivering a four-quarter average earnings surprise of 151.67%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe
Johnson & Johnson (JNJ - Free Report) announced that it has submitted a supplemental new drug application (sNDA) seeking expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States.
Prezcobix is a two-drug fixed-dose combination tablet for treating HIV-1 infection in treatment-naïve and treatment-experienced adults and adolescent patients weighing at least 40 kg. It combines darunavir, J&J’s HIV-1 protease inhibitor, and cobicistat, Gilead Sciences’ (GILD - Free Report) CYP3A inhibitor. J&J markets darunavir as Prezista, as a single agent, in the United States and Gilead markets cobicistat by the name of Tybost.
So far this year, J&J’s shares have declined 5.7% against the industry’s 17.3% increase.
Image Source: Zacks Investment Research
The sNDA seeks approval of Prezcobix for treatment-naïve and treatment-experienced pediatric patients aged 6 and older weighing at least 25 kg who have no viral resistance mutations associated with darunavir. A similar label expansion application has also been submitted to the European Medicines Agency (EMA) for expanded use of Rezolsta for pediatric patients in Europe. Rezolsta is Prezcobix’s brand name in Europe.
Prezcobix/Rezolsta is also marketed under a collaboration between J&J and Gilead. The companies have developed a separate new combination tablet containing a weight-adjusted pediatric dose (darunavir 675 mg/cobicistat 150 mg) for younger kids.
Other than Prezista and Prezcobix/Rezolsta, J&J also markets a darunavir-based once-daily single-tablet regimen (STR) called Symtuza.
Other than J&J and Gilead, another key player in the HIV market is GSK plc (GSK - Free Report) via its HIV subsidiary, ViiV Healthcare. GSK generates the majority of its HIV sales from its dolutegravir franchise, comprising three-drug regimens — Triumeq and Tivicay — and two-drug regimens — Dovato and Juluca. Some of its new long-acting medicines are Cabenuva and Apretude, which are also witnessing strong patient demand and contributing to sales growth. GSK’s HIV sales rose 13% at constant exchange rates in 2023. HIV sales are projected to grow in the high single-digit to low double-digit range in 2024.
Zacks Rank and Stock to Consider
J&J currently has a Zacks Rank #3 (Hold).
Johnson & Johnson Price and Consensus
Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote
A top-ranked stock in the healthcare sector is Bioventus (BVS - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, 2024 estimates for Bioventus have improved from 16 cents per share to 27 cents per share. For 2025, earnings estimates have improved from 40 cents to 43 cents per share in the past 60 days. So far this year, shares of BVS are up 27.1%.
Earnings of Bioventus beat estimates in three of the last four quarters while missing in one, delivering a four-quarter average earnings surprise of 151.67%.